# Vivos Therapeutics Inc. (VVOS)

Source: https://www.quantisnow.com/company/VVOS
Generated: 2026-11-08T08:18:08.108Z

- Ticker: VVOS
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Medical/Dental Instruments
- IPO year: 2020
- SEC CIK: 0001716166
- Website: vivoslife.com

## About

Vivos Therapeutics, Inc., a medical technology company, engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing, such as mild-to-moderate obstructive sleep apnea (OSA). Its treatment, the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of mild to moderate OSA. Vivos Therapeutics also offers VivoScore, a comprehensive home sleep apnea test. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.

## Latest VVOS news and filings

- 2026-11-02 11:02 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Vivos Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-vivos-therapeutics-inc-6765901)
- 2026-10-29 19:55 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Vivos Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-vivos-therapeutics-inc-6763269)
- 2026-10-27 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Vivos Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-vivos-therapeutics-inc-6759213)
- 2026-10-27 01:52 UTC [SEC Form 4] [SEC Form 4 filed by Vivos Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-vivos-therapeutics-inc-6758145)
- 2026-10-27 00:06 UTC [SEC Form 4] [SEC Form 4 filed by Vivos Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-vivos-therapeutics-inc-6758125)
- 2026-10-21 20:15 UTC [SEC Form PRER14A filed by Vivos Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-prer14a-filed-by-vivos-therapeutics-inc-6753612)
- 2026-10-21 11:00 UTC [SEC Form 8-K] [SEC Form 8-K filed by Vivos Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-vivos-therapeutics-inc-6752849)
- 2026-10-21 11:00 UTC [Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard](https://www.quantisnow.com/insight/vivos-therapeutics-reports-nasdaq-confirmation-of-compliance-with-continued-listing-6752805)
- 2026-10-19 20:58 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Vivos Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-vivos-therapeutics-inc-6750916)
- 2026-10-19 21:01 UTC [Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel](https://www.quantisnow.com/insight/vivos-therapeutics-closes-acquisition-of-stake-in-sod-sciences-and-6750915)
- 2026-10-19 20:49 UTC [SEC Form 8-K] [SEC Form 8-K filed by Vivos Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-vivos-therapeutics-inc-6750888)
- 2026-10-15 12:45 UTC [SEC Form 8-K] [SEC Form 8-K filed by Vivos Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-vivos-therapeutics-inc-6747490)
- 2026-10-15 12:45 UTC [Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test](https://www.quantisnow.com/insight/vivos-therapeutics-agrees-to-acquire-minority-stake-in-sod-sciences-6747471)
- 2026-10-01 01:54 UTC [SEC Form 8-K] [Vivos Therapeutics Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits](https://www.quantisnow.com/insight/vivos-therapeutics-inc-filed-sec-form-8-k-changes-in-registrants-6731211)
- 2026-09-29 12:45 UTC [Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives](https://www.quantisnow.com/insight/vivos-therapeutics-reports-progress-in-material-cost-reductions-and-revenue-6728700)
- 2026-09-19 00:20 UTC [SEC Form 4] [SEC Form 4 filed by Director Sokolow Leonard J](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-sokolow-leonard-j-6721001)
- 2026-09-19 00:17 UTC [SEC Form 4] [SEC Form 4 filed by Director Johnson Gregg C](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-johnson-gregg-c-6720999)
- 2026-09-18 21:04 UTC [SEC Form 4] [Chief Executive Officer Huntsman Ronald Kirk acquired $50,000 worth of Preferred Stock (85,910 units at $0.58) (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-huntsman-ronald-kirk-acquired-50000-worth-of-6720817)
- 2026-09-08 21:29 UTC [SEC Form 8-K] [Amendment: Vivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits](https://www.quantisnow.com/insight/amendment-vivos-therapeutics-inc-filed-sec-form-8-k-entry-into-6708769)
- 2026-09-08 12:45 UTC [Vivos Therapeutics Announces Material Debt Reduction](https://www.quantisnow.com/insight/vivos-therapeutics-announces-material-debt-reduction-6707720)
- 2026-09-04 22:26 UTC [SEC Form 8-K] [Vivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits](https://www.quantisnow.com/insight/vivos-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6707206)
- 2026-08-28 12:45 UTC [Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center](https://www.quantisnow.com/insight/vivos-therapeutics-and-south-palm-cardiovascular-associates-sign-definitive-agreements-6698007)
- 2026-08-26 20:10 UTC [SEC Form 4] [Principal Accounting Officer Amman Bradford K. was granted 250,000 shares, increasing direct ownership by 312,500% to 250,080 units (SEC Form 4)](https://www.quantisnow.com/insight/principal-accounting-officer-amman-bradford-k-was-granted-250000-shares-6695615)
- 2026-08-25 12:45 UTC [Dividends] [Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers](https://www.quantisnow.com/insight/vivos-therapeutics-reports-record-new-patient-referrals-at-its-nevada-6693742)
- 2026-08-21 21:30 UTC [SEC Form 8-K] [Vivos Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/vivos-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6691748)
- 2026-08-20 14:24 UTC [Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment](https://www.quantisnow.com/insight/vivos-therapeutics-opens-new-sleep-testing-and-treatment-facility-in-6689746)
- 2026-08-14 20:28 UTC [Earnings Date] [Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update](https://www.quantisnow.com/insight/vivos-therapeutics-reports-second-quarter-2026-financial-results-and-provides-6683115)
- 2026-08-14 14:29 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Vivos Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-vivos-therapeutics-inc-6682263)
- 2026-08-14 12:45 UTC [Earnings Date] [Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call](https://www.quantisnow.com/insight/vivos-therapeutics-schedules-release-of-second-quarter-2026-financial-results-6682040)
- 2026-08-11 21:02 UTC [SEC Form 8-K] [Vivos Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/vivos-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6676380)
- 2026-08-11 12:45 UTC [Vivos Therapeutics Expands Greenway Health Partnership to Deploy AI-Enabled Platform Across All Clinical and Revenue Operations](https://www.quantisnow.com/insight/vivos-therapeutics-expands-greenway-health-partnership-to-deploy-ai-enabled-platform-6675156)
- 2026-08-05 12:30 UTC [Vivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device Technology](https://www.quantisnow.com/insight/vivos-therapeutics-announces-issuance-of-new-us-patent-broadening-protection-6664167)
- 2026-08-03 21:29 UTC [SEC Form 8-K] [Vivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/vivos-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6660412)
- 2026-07-15 20:23 UTC [SEC Form 4] [SEC Form 4 filed by Large owner Skaff Michael C](https://www.quantisnow.com/insight/sec-form-4-filed-by-large-owner-skaff-michael-c-6638389)
- 2026-07-15 20:22 UTC [SEC Form 3] [SEC Form 3 filed by new insider V-Co Investors 4 Llc](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-v-co-investors-4-6638381)
- 2026-07-07 21:29 UTC [SEC Form 8-K] [Vivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Financial Statements and Exhibits](https://www.quantisnow.com/insight/vivos-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6630493)
- 2026-06-30 12:45 UTC [Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants](https://www.quantisnow.com/insight/vivos-vida-appliance-shows-statistically-significant-improvement-in-insomnia-severity-6620202)
- 2026-06-25 21:22 UTC [SEC Form 8-K] [Vivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/vivos-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6616317)
- 2026-06-22 12:30 UTC [Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity](https://www.quantisnow.com/insight/vivos-therapeutics-and-streeterville-extend-timeframe-of-strategic-financing-agreement-6610149)
- 2026-06-16 21:03 UTC [SEC Form 8-K] [Vivos Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/vivos-therapeutics-inc-filed-sec-form-8-k-other-events-financial-6605229)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/VVOS
- Earnings history: https://www.quantisnow.com/earnings/VVOS
- Dividend history: https://www.quantisnow.com/dividends/VVOS
- Insider transactions: https://www.quantisnow.com/insiders/VVOS
- Options chain: https://www.quantisnow.com/options/VVOS
- SEC 8-K filings only: https://www.quantisnow.com/company/VVOS/8-k
- RSS and alerts for VVOS: https://www.quantisnow.com/docs/rss-feeds.md